HALO
Halozyme Therapeutics Inc.
$65.36
-$1.23(-1.85%)
56
Overall
60
Value
45
Tech
63
Quality
Market Cap
$7.50B
Volume
1.40M
52W Range
$47.50 - $82.22
Target Price
$83.11
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $146.7M | $316.6M | $151.9M | $196.0M | $267.6M | $443.3M | $660.1M | $829.3M | $1.0B | $1.4B | ||
| Total Revenue | $53.4M | $50.4M | $151.9M | $196.0M | $267.6M | $443.3M | $660.1M | $829.3M | $1.0B | $1.4B | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-33.2M | $-31.2M | $-10.1M | $45.5M | $43.4M | $81.4M | $139.3M | $192.4M | $159.4M | $228.8M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $113.5M | $285.5M | $141.7M | $150.4M | $224.2M | $361.9M | $520.8M | $636.9M | $855.9M | $1.2B | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $196.7M | $204.5M | $211.1M | $218.1M | $80.0M | $86.0M | $253.3M | $299.3M | $304.4M | $650.1M | ||
| Research & Development | $150.8M | $150.6M | $150.3M | $140.8M | $34.2M | $35.7M | $66.6M | $76.4M | $79.0M | $366.4M | ||
| Research Expense | $150.8M | $150.6M | $150.3M | $140.8M | $34.2M | $35.7M | $66.6M | $76.4M | $79.0M | $81.5M | ||
| Selling, General & Administrative | $45.9M | $53.8M | $60.8M | $77.3M | $45.7M | $50.3M | $143.5M | $149.2M | $154.3M | $207.1M | ||
| Selling & Marketing Expenses | $45.9M | $53.8M | $60.8M | -- | -- | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $-2.2M | $-2.3M | $-2.5M | $77.3M | $45.7M | $50.3M | $143.5M | $149.2M | $154.3M | $207.1M | ||
| Salaries & Wages | $-25.6M | $-30.7M | $-35.7M | -- | -- | -- | $24.4M | -- | -- | -- | ||
| Depreciation & Amortization | $-2.4M | $-2.2M | $-2.4M | $4.1M | $3.3M | $3.0M | $43.1M | $73.8M | $71.0M | $76.7M | ||
| Depreciation & Amortization | $-2.4M | $-2.2M | $-2.4M | $4.1M | $3.3M | $3.0M | $43.1M | $73.8M | $71.0M | $76.7M | ||
| Amortization | -- | -- | $-1.5M | $2.5M | $14.1M | $3.6M | $43.1M | $73.8M | $71.0M | $76.7M | ||
| Other Operating Expenses | $-61.6M | $-63.6M | $-60.3M | $-1.4M | -- | -- | $-787.0K | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-83.2M | $81.0M | $-69.3M | $-67.6M | $144.3M | $275.9M | $267.5M | $337.6M | $551.5M | $469.0M | ||
| EBITDA | $-76.0M | $87.3M | $-60.9M | $-56.5M | $153.0M | $259.0M | $323.4M | $459.3M | $663.9M | $580.6M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $20.0M | $22.0M | $18.0M | $11.6M | $20.4M | $7.5M | $16.9M | $18.8M | $18.1M | $18.1M | ||
| Net Non-Operating Interest Income/Expense | $-20.0M | $-22.0M | $-18.0M | $-11.6M | $-20.4M | $-7.5M | $-16.9M | $-18.8M | $-18.1M | $-18.1M | ||
| Other Income/Expense | $-1.3M | $-2.6M | $-7.6M | $-7.0M | $-5.4M | $19.9M | $-1.7M | $-16.3M | $-23.8M | $32.7M | ||
| Other Special Charges | $1.3M | $2.6M | $7.6M | $7.0M | $5.4M | $-19.9M | $-1.7M | $16.3M | $23.8M | $16.0M | ||
| SPECIAL ITEMS | ||||||||||||
| Other Impairment Of Capital Assets | -- | -- | -- | $1.1M | $577.0K | -- | -- | -- | -- | $48.7M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-81.9M | $83.6M | $-61.8M | $-60.6M | $149.7M | $256.0M | $265.9M | $367.1M | $575.2M | $485.0M | ||
| Pre-Tax Income | $-101.9M | $61.6M | $-79.8M | $-72.3M | $129.3M | $248.5M | $248.9M | $348.3M | $557.1M | $466.9M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $1.2M | $-1.4M | $537.0K | $-11.0K | $217.0K | $-154.2M | $46.8M | $66.7M | $113.0M | $150.0M | ||
| NET INCOME | ||||||||||||
| Net Income | $-103.0M | $63.0M | $-80.3M | $-72.2M | $129.1M | $402.7M | $202.1M | $281.6M | $444.1M | $316.9M | ||
| Net Income (Continuing Operations) | $-103.0M | $63.0M | $-80.3M | $-72.2M | $129.1M | $402.7M | $202.1M | $281.6M | $444.1M | $316.9M | ||
| Net Income (Discontinued Operations) | $-103.0M | $63.0M | $-80.3M | $-72.2M | $129.1M | $402.7M | $202.1M | $281.6M | $444.1M | $316.9M | ||
| Net Income (Common Stockholders) | $-103.0M | $63.0M | $-80.3M | $-72.2M | $129.1M | $402.7M | $202.1M | $281.6M | $444.1M | $316.9M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $205.3M | -- | -- | $510.9M | ||
| TOTALS | ||||||||||||
| Total Expenses | $163.5M | $173.3M | $200.9M | $263.6M | $123.3M | $167.4M | $392.6M | $491.7M | $463.8M | $878.9M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $128.0M | $136.4M | $143.6M | $288.7M | $136.2M | $140.6M | $136.8M | $131.9M | $126.8M | $119.8M | ||
| Average Shares Outstanding (Diluted) | $129.2M | $139.1M | $143.6M | $144.3M | $141.5M | $146.8M | $140.6M | $134.2M | $129.4M | $123.9M | ||
| Shares Outstanding | $129.8M | $143.1M | $145.0M | $138.2M | $135.3M | $137.7M | $135.4M | $126.8M | $246.3M | $118.0M | ||
| Basic EPS | $0.03 | $0.46 | $-0.56 | $-0.50 | $0.95 | $2.86 | $1.48 | $2.13 | $3.5 | $2.64 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | $-0.50 | $0.95 | $2.86 | $1.48 | $2.13 | $3.5 | $2.64 | ||
| Diluted EPS | $-0.81 | $0.45 | $-0.56 | $-0.50 | $0.91 | $2.74 | $1.44 | $2.1 | $3.43 | $2.56 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $-0.50 | $0.91 | $2.74 | $1.44 | $2.1 | $3.43 | $2.56 | ||
| OTHER METRICS | ||||||||||||
| Development Expense | -- | -- | -- | -- | -- | -- | -- | -- | -- | $284.9M | ||
| Gain On Sale Of P P E | -- | -- | $-5.0K | $-1.4M | $772.0K | -- | -- | -- | -- | -- | ||
| Other Gand A | $-2.2M | $-2.3M | $-2.5M | $77.3M | $45.7M | $50.3M | $143.5M | $149.2M | $154.3M | $207.1M | ||
| Rent And Landing Fees | $-2.2M | $-2.3M | $-2.5M | $2.7M | $2.3M | -- | -- | -- | -- | -- | ||
| Selling Expense | $45.9M | $53.8M | $60.8M | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | HALO | $65.36 | -1.8% | 1.40M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Halozyme Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW